By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Choose which cookies you allow
Necessary Required for the site to work, such as remembering this choice. Always active

AASLD Logo
IDSA Logo
Resource Library
  • Home
    • Table of Contents
    • Introductions
    • Methods
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
  • Test, Evaluate, Monitor
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
  • Treatment-Naive
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
    • Genotype 1
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
    • Genotype 2
      • GT2: No Cirrhosis
      • GT2: Compensated
    • Genotype 3
      • GT3: No Cirrhosis
      • GT3: Compensated
    • Genotype 4
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
  • Treatment-Experienced Patients
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
  • Unique & Key Populations
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
    • PWID, MSM & Corrections
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
  • About
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
AASLD Logo
IDSA Logo
    • Table of Contents
    • Introductions
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
      • GT2: No Cirrhosis
      • GT2: Compensated
      • GT3: No Cirrhosis
      • GT3: Compensated
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
Resource Library
  • National trends and outcomes of heart-kidney transplantation using hepatitis C positive donors

    August 23, 2022
  • Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis

    August 23, 2022
  • Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics

    August 22, 2022
  • Efficacy and safety of 8- or 12 weeks of glecaprevir/pibrentasvir in patients with evidence of portal hypertension

    August 22, 2022
  • Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

    August 17, 2022
  • Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis

    August 7, 2018
  • Hepatitis C screening of the “birth cohort” (born 1945-1965) and younger inmates of New York City jails

    April 20, 2018
  • Opt-out HIV and hepatitis C testing at the Dallas county jail: uptake, prevalence, and demographic characteristics of testers

    April 20, 2018
  • A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections

    April 20, 2018
  • Is antenatal screening for hepatitis C virus cost-effective? A decade’s experience at a London centre

    April 19, 2018
1 2 3 … 30
Next Page
AASLD Logo
IDSA Logo
  • Test, Evaluate, Monitor
  • Treatment-Naive
  • Treatment-Experienced Patients
  • Key Populations With HCV Infection
  • Resource Library
  • About Us
  • Announcements
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Accessibility

© 2025 HCV Guidelines All right reserved.

Website by Yoko Co